News

MorphoSys AG and Constellation Pharmaceuticals, Inc. announced that they have entered into a definitive agreement whereby MorphoSys will acquire Constellation for $34.00 per share in…
Read More...

Centivax Inc. announced that it has entered into a strategic partnership with the U.S. Naval Medical Research Center (NMRC) for Phase I clinical development of Centi-B9, Centivax's…
Read More...

Primordial Genetics a synthetic biology company developing enzymatic production systems for nucleic acids,  announced granting Arcturus Therapeutics Holdings Inc. a clinical-stage…
Read More...

GenScript Biotech Corporation along with its subsidiary, GenScript ProBio, and Ligand Pharmaceuticals Incorporated announced that they have entered into a strategic licensing agreement…
Read More...

Amgen and Kyowa Kirin Co., Ltd. announced an agreement to jointly develop and commercialize KHK4083, which is Kyowa Kirin's potential first-in-class, Phase 3-ready anti-OX40 fully human…
Read More...

Moderna, Inc. a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines announced that it has entered into an agreement with Thermo Fisher Scientific (NYSE: TMO)…
Read More...

POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, announced today that the U.S.…
Read More...

Alkermes plc announced that the U.S. Food and Drug Administration (FDA) has approved LYBALVI (olanzapine and samidorphan) for the treatment of adults with schizophrenia and for the…
Read More...

NRx Pharmaceuticals announced it has filed an application with U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for ZYESAMI (Aviptadil-acetate), to…
Read More...

Amgen and Kyowa Kirin Co., Ltd. announced an agreement to jointly develop and commercialize KHK4083, which is Kyowa Kirin's potential first-in-class, Phase 3-ready anti-OX40 fully human…
Read More...

ADVANZ PHARMA Corp. Limited a specialty pharmaceutical company with a strategic focus on complex medicines in Europe, announced the completion of its acquisition by a subsidiary of…
Read More...

Nexturn Bio Inc., a subsidiary of Nexturn Bioscience Co., Ltd., announced on May 26th that it had acquired a 50% stake in RosVivo Therapeutics Inc. ("Rosvivo"), an American new drug…
Read More...

AnHeart Therapeutics Co., Ltd. a clinical stage oncology company focused on underserved patients in global markets, and Innovent Biologics, Inc. an innovative leading biopharmaceutical…
Read More...

Samsung Biologics announced its plans to add mRNA vaccine drug substance (DS) manufacturing capability to the current facility in Songdo, ready for cGMP operations within the earlier…
Read More...

Antengene Corporation Limited announced the dosing of the first patient in China in a Phase I/II trial (the HATCH trial) of eltanexor (ATG-016), a next-generation selective inhibitor of…
Read More...

AstraZeneca’s Tagrisso (osimertinib) has been approved in the European Union (EU) for the adjuvant treatment of adult patients with early-stage (IB, II and IIIA) epidermal growth factor…
Read More...

Novartis and Molecular Partners announced the start of the clinical trial EMPATHY, a Phase 2 and 3 study, to explore the use of its novel DARPin therapeutic candidate ensovibep (MP0420)…
Read More...

Menarini Silicon Biosystems, a pioneer of liquid biopsy and single cell technologies, announced the launch of the new highly automated DEPArray PLUS, now available with 9 fluorescent…
Read More...

Seelos Therapeutics, Inc. announced it has received European Orphan Drug Designation for SLS-005 in amyotrophic lateral sclerosis (ALS) from the European Medicines Agency (EMA)…
Read More...

Prestige Consumer Healthcare Inc. announced that it has entered into a definitive agreement to acquire a portfolio of over-the-counter consumer brands from specialty pharmaceutical…
Read More...